Anthony Liu

Project Investigator, SickKids Research Institute

Dr. Anthony Liu joined the staff at The Hospital for Sick Children (SickKids) in 2024. Dr Liu obtained his Medical Degree with Honours from the University of Hong Kong, and completed his Paediatric and Paediatric Haematology/Oncology training in Queen Mary Hospital, Hong Kong. Subsequently, he pursued a Clinical and Research Fellowship in Paediatric Neuro-Oncology at St. Jude Children’s Research Hospital, spearheading landmark studies on circulating tumour DNA analysis for medulloblastoma and molecular profiling in rare CNS embryonal tumours. Before his transition to Toronto, Dr Liu served as attending Paediatric Haematologist/Oncologist at Hong Kong Children’s Hospital, dedicating effort in parallel for capacity building in Paediatric Neuro-Oncology with providers from Asia.

Education and experience

• 2024–Present: Staff Neuro-Oncologist, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
• 2024–Present: Honorary Clinical Assistant Professor, Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong
• 2021–Present: Honorary Associate Consultant, Hong Kong Children’s Hospital, Hong Kong
• 2016–2024: Clinical Assistant Professor, Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong
• 2022: First Fellow in Paediatric Haematology/Oncology, Hong Kong Academy of Medicine, Hong Kong
• 2017–2020: Paediatric Neuro-Oncology Fellow, St. Jude Children’s Research Hospital, Memphis, TN, USA
• 2016: FHKAM (Paed), FHKCPaed (Specialist in Paediatrics), Hong Kong Academy of Medicine, Hong Kong
• 2010–2016: Paediatric Resident, Queen Mary Hospital, Hong Kong
• 2013: M.Med.Sc. (Genetic Counseling), The University of Hong Kong, Hong Kong
• 2012: MRCPCH, RCPCH, UK
• 2009–2010: Intern, Queen Mary Hospital, Hong Kong
• 2009: MBBS (Distinction in Pediatrics, Obstetrics, and Gynecology), The University of Hong Kong, Hong Kong

1. Liu APY, Li BK, Vasiljevic A, Dewan MC, Tamrazi B, Ertl-Wagner B, Hansford JR, Pfaff E, Mynarek M, Ng HK, Tsang DS, Gottardo NG, Gajjar A, Bouffet E, Dufour C, Pizer B, Schiff D, Jenkinson MD, Lombardi G, Wen PY, van den Bent MJ, Huang A. SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors. Neuro Oncol. 2024 Jul 29: noae128.
2. Liu APY, Li KKW, Chow C, Chan S, Leung AWK, Shing MMK, To KF, Chan DTM, Chan GCF, Ng HK. Expanding the clinical and molecular spectrum of DICER1-altered pituitary neoplasms. Acta Neuropathologica. 2022 Jun3;143(3):415-417. 
3. Liu APY, Smith KS, Kumar R, Paul L, Bihannic L, Lin T, Maass KK, Pajtler KW, Chintagumpala M, Su JM, Bouffet E, Fisher MJ, Gururangan S, Cohn R, Hassall T, Hansford JR, Klimo P Jr, Boop FA, Stewart CF, Harreld JH, Merchant TE, Tatevossian RG, Neale G, Lear M, Klco JM, Orr BA, Ellison DW, Gilbertson RJ, Onar-Thomas A, Gajjar A, Robinson GW, Northcott PA. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell. 2021 Nov 8;39(11):1519-1530.e4.
4. Liu APY, Gudenas B, Lin T, Orr BA, Klimo P Jr, Kumar R, Bouffet E, Gururangan S, Crawford JR, Kellie SJ, Chintagumpala M, Fisher MJ, Bowers DC, Hassall T, Indelicato DJ, Onar-Thomas A, Ellison DW, Boop FA, Merchant TE, Robinson GW, Northcott PA, Gajjar A. Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathologica. 2020 Feb;139(2):259-271.
5. Liu AP, Zhen Z, Yang Q, Yuan X, Ma X, Chen J, Wang J, Yang L, Guo H, Jiang L, Weng W, Huang L, Liu W, Wang J, Wu S, Zeng J, Jiang M, He K, Ge M, Cheng KK, Ho WW, Li C, Yu L, Zhu S, Ng HK, Chan GC, Sun X. Treatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children's Cancer Group (CCCG). Neurooncology Advances. 2021 Sep 17;3(1):vdab134.

See a full list of Anthony Liu's publications